NCT04168203View on ClinicalTrials.gov

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

PHASE4CompletedINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

April 8, 2025

Conditions

Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism

Interventions

DRUG

Apixaban 2.5 MG

apixaban 2.5 mg orally twice daily for a duration of 12 months

DRUG

Placebo oral tablet

placebo oral tables twice daily for a duration of 12 months

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04168203 - Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism | Biotech Hunter | Biotech Hunter